DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Nedaplatin is an investigational drug.
There have been 38 clinical trials for Nedaplatin. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2013.
The most common disease conditions in clinical trials are Carcinoma, Nasopharyngeal Neoplasms, and Esophageal Neoplasms. The leading clinical trial sponsors are Sun Yat-sen University, Chinese Academy of Medical Sciences, and Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.
There are two US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Nedaplatin
|Single-arm, Open-label, Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma||Jiangsu HengRui Medicine Co., Ltd.||Phase 2|
|Single-arm, Open-label, Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma||The First Affiliated Hospital of Zhengzhou University||Phase 2|
|Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC||Fuzhou General Hospital||Phase 2|
Top disease conditions for Nedaplatin
Top clinical trial sponsors for Nedaplatin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Nedaplatin||Start Trial||Estrogen-linked platinum (II) complexes as anticancer agents||Berube; Gervais (Trois-Riviere, CA)||Start Trial|
|Nedaplatin||Start Trial||Macromolecular platinum chelates||Access Pharmaceuticals, Inc. (Dallas, TX)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Nedaplatin||World Intellectual Property Organization (WIPO)||2005002508||2023-06-11||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|